VIDEO: Sapien 3 TAVR bests surgery in intermediate-risk patients
April 6, 2016|Cardiology News
Author and Disclosure Information
AT ACC 16
The remarkable outcomes in regard to mortality and stroke are “clinically meaningful and some of the best outcomes we’ve ever witnessed with transcatheter therapy,” he said.
This study was funded by Edwards Lifesciences. Dr. Thourani disclosed that he has received consulting fees and/or research grants from Edwards Lifesciences, St. Jude Medical, Abbott Medical, Boston Scientific, Claret Medical, DirectFlow, Medtronic, and Sorin. Dr. Kandzari has received consultant fees and honoraria from Boston Scientific, The Medicines Company, and Medtronic.
